Shire taps Rani Therapeutics’ oral delivery tech for hemophilia therapy

This article was originally published here
Share

ShireShire (NSDQ:SHPG) said this week that it is collaborating with Rani Therapeutics to combine the company’s Rani Pill technology for the delivery of factor VIII therapy in patients with hemophilia A.

According to the terms of the deal, Shire has the exclusive option to negotiate a license to develop and commercialize the technology as a delivery mechanism for FVIII therapy after the companies conduct feasibility studies. Shire also made an equity investment into Rani Therapeutics as part of the collaboration.

Get the full story at our sister site, Drug Delivery Business News.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply